Search Results - "Vormoor, Britta"

MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance by van der Zwet, Jordy C. G., Buijs-Gladdines, Jessica G. C. A. M., Cordo’, Valentina, Debets, Donna O., Smits, Willem K., Chen, Zhongli, Dylus, Jelle, Zaman, Guido J. R., Altelaar, Maarten, Oshima, Koichi, Bornhauser, Beat, Bourquin, Jean-Pierre, Cools, Jan, Ferrando, Adolfo A., Vormoor, Josef, Pieters, Rob, Vormoor, Britta, Meijerink, Jules P. P.

“…(Patho-)physiological activation of the IL7-receptor (IL7R) signaling contributes to steroid resistance in pediatric T-cell acute lymphoblastic leukemia…”
Get full text

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial by Menne, Tobias, Slade, Daniel, Savage, Joshua, Johnson, Sarah, Irving, Julie, Kearns, Pamela, Plummer, Ruth, Shenton, Geoff, Veal, Gareth J, Vormoor, Britta, Vormoor, Josef, Billingham, Lucinda

“…IntroductionEvent-free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30%–50%, with 5-year…”
Get full text

Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging by Vormoor, Britta, Knizia, Henrike K, Batey, Michael A, Almeida, Gilberto S, Wilson, Ian, Dildey, Petra, Sharma, Abhishek, Blair, Helen, Hide, I Geoff, Heidenreich, Olaf, Vormoor, Josef, Maxwell, Ross J, Bacon, Chris M

“…Ewing sarcoma and osteosarcoma represent the two most common primary bone tumours in childhood and adolescence, with bone metastases being the most adverse…”
Get full text

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study by Brivio, Erica, Locatelli, Franco, Thano, Adriana, Petit, Arnaud, Vormoor, Britta Julia, Rives, Susana, Bielorai, Bella, Rossig, Claudia, Rizzari, Carmelo, Van Der Velden, Vincent H.J., Ammerlaan, Anneke C.J., Den Boer, Monique L., Sleight, Barbara, Engstler, Gernot, Stary, Jan, Bautista Sirvent, Francisco José, Chen-Santel, Christiane, Bruno, Bénédicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, von Stackelberg, Arend, Zwaan, Christian Michel

“…▪ Background: Inotuzumab ozogamicin (InO) was well tolerated and demonstrated anti-leukemia activity in heavily pre-treated pediatric patients (pts) with…”
Get full text

Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma by Brivio, Erica, Baruchel, André, Beishuizen, Auke, Bourquin, Jean-Pierre, Brown, Patrick A., Cooper, Todd, Gore, Lia, Kolb, E. Anders, Locatelli, Franco, Maude, Shannon L., Mussai, Francis J., Vormoor-Bürger, Britta, Vormoor, Josef, von Stackelberg, Arend, Zwaan, C. Michel

“…Despite improved outcomes achieved in the last decades for children with newly diagnosed leukaemia and lymphoma, treatment of patients with refractory/relapsed…”
Get full text

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial by Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H. J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J. C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, Zwaan, Christian M.

“…Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic…”
Get full text

CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study by Jacoby, Elad, Ghorashian, Sara, Vormoor, Britta, De Moerloose, Barbara, Bodmer, Nicole, Molostova, Olga, Yanir, Asaf D, Buechner, Jochen, Elhasid, Ronit, Bielorai, Bella, Rogosic, Srdan, Dourthe, Marie-Emilie, Maschan, Michael, Rossig, Claudia, Toren, Amos, von Stackelberg, Arend, Locatelli, Franco, Bader, Peter, Zimmermann, Martin, Bourquin, Jean Pierre, Baruchel, Andre

“…Relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) may occur in the central nervous system (CNS). Most clinical trials of CAR T-cell therapy…”
Get full text

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma by Vormoor, Britta, Curtin, Nicola J

“…PURPOSE OF REVIEWIn 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP)…”
Get full text

The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study by Vormoor, Britta Julia, Menne, Tobias, Savage, Joshua, Patel, Amit, Castleton, Anna, Fielding, Adele Kay, Lancaster, Donna, Latif, Anne Louise, Morley, Nick, Shenton, Geoff, Veal, Gareth, Irving, Julie, Kearns, Pam, Billingham, Lucinda, Vormoor, Josef

“…Introduction Relapsed acute lymphoblastic leukemia (ALL) is a major therapeutic challenge and novel treatment strategies are urgently sought. RAS-pathway…”
Get full text

Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia by Ceolin, Valeria, Brivio, Erica, Rheingold, Susan R., Leahy, Allison Barz, Vormoor, Britta Julia, O'Brien, Maureen M., Rubinstein, Jeremy, Kalwak, Krzysztof, De Moerloose, Barbara, Jacoby, Elad, Bader, Peter, Fuster, José L., Locatelli, Franco, Hoogerbrugge, Peter, Calkoen, Friso, Zwaan, Christian M.

“…▪ Background: Chimeric Antigen Receptor T-cells targeting CD19 (CART-19) have shown promising efficacy for relapsed/refractory (R/R) B-cell precursor acute…”
Get full text

Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia by Ceolin, Valeria, Brivio, Erica, van Tinteren, Harm, Rheingold, Susan R., Leahy, Allison, Vormoor, Britta, O’Brien, Maureen M., Rubinstein, Jeremy D., Kalwak, Krzysztof, De Moerloose, Barbara, Jacoby, Elad, Bader, Peter, López-Duarte, Mónica, Goemans, Bianca F., Locatelli, Franco, Hoogerbrugge, Peter, Calkoen, Friso G., Zwaan, Christian Michel

“…Chimeric antigen receptor T cells targeting CD19 (CART-19) have shown remarkable efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic…”
Get full text

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement by Jacoby, Elad, Ghorashian, Sara, Vormoor, Britta Julia, De Moerloose, Barbara, Bodmer, Nicole, Maschan, Michael, Yanir, Asaf David, Bielorai, Bella, Rogosic, Srdan, Molostova, Olga, Rossig, Claudia, Toren, Amos, von Stackelberg, Arend, Bourquin, Jean-Pierre

“…Background: CAR T cells targeting CD19 are approved for patients with relapsed or refractory acute lymphoblastic leukemia (ALL), failing two or more prior…”
Get full text

Fludarabine Exposure Predicts Outcome after CD19 CAR T Cell Therapy in Children and Young Adults with Acute Leukemia; An Exploratory, Observational Study by Dekker, Linde, Calkoen, Friso, Jiang, Yilin, Blok, Hilly, Spoon, Maike, Admiraal, Rick, Hoogerbrugge, Peter, Vormoor, Britta Julia, Vormoor, Josef, Zwaan, C. Michel, Visscher, Henk, Bierings, Marc, Van Der Vlugt, Marieke, Van Tinteren, Harm, Nijstad, A. Laura, Van Der Elst, Kim, Huitema, Alwin D.R., Pieters, Rob, Lindemans, Caroline, Nierkens, Stefan

“…The addition of fludarabine to cyclophosphamide as lymphodepleting regimen prior to adoptive transfer of CD19 chimeric antigen receptor (CAR) T cells…”
Get full text

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2 by Vormoor, Britta, Schlosser, Yvonne T, Blair, Helen, Sharma, Abhishek, Wilkinson, Sarah, Newell, David R, Curtin, Nicola

“…DNA-PK and PARP inhibitors sensitize cancer cells to chemo- and radiotherapy. ETS transcription factors (EWS-FLI1) have been described as biomarkers for…”
Get full text

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL by Van Der Zwet, Jordy C.G., Buijs-Gladdines, Jessica G.C.A.M., Cordo', Valentina, Debets, Donna, Smits, Willem K., Chen, Zhongli, Dylus, Jelle, Zaman, Guido, Altelaar, Maarten, Oshima, Koichi, Bornhauser, Beat, Bourquin, Jean-Pierre, Cools, Jan, Ferrando, Adolfo A., Vormoor, Josef, Pieters, Rob, Vormoor, Britta Julia, Meijerink, Jules P.P.

“…Introduction Poor prednisolone response in the induction phase of treatment is a risk-stratification marker in the current Dutch DCOG ALL-11 treatment…”
Get full text

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia by Dekker, Linde, Calkoen, Friso G., Jiang, Yilin, Blok, Hilly, Veldkamp, Saskia R., De Koning, Coco, Spoon, Maike, Admiraal, Rick, Hoogerbrugge, Peter, Vormoor, Britta, Vormoor, H. Josef, Visscher, Henk, Bierings, Marc, Van Der Vlugt, Marieke, Van Tinteren, Harm, Nijstad, A. Laura, Huitema, Alwin D.R., Van Der Elst, Kim C.M., Pieters, Rob, Lindemans, Caroline A., Nierkens, Stefan

“…The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to CD19 chimeric antigen receptor (CAR) T-cell therapy significantly…”
Get full text

127 - Fludarabine Exposure Predicts Outcome after CD19 CAR T Cell Therapy in Children and Young Adults with Acute Leukemia; An Exploratory, Observational Study by Dekker, Linde, Calkoen, Friso, Jiang, Yilin, Blok, Hilly, Spoon, Maike, Admiraal, Rick, Hoogerbrugge, Peter, Vormoor, Britta, Vormoor, Josef, Zwaan, C. Michel, Visscher, Henk, Bierings, Marc, Van Der Vlugt, Marieke, Van Tinteren, Harm, Laura Nijstad, A., Huitema, Alwin D.R., Van Der Elst, Kim, Pieters, Rob, Lindemans, Caroline A., Nierkens, Stefan

Get full text

Fludarabine Exposure Predicts Outcome after CD19 CAR T Cell Therapy in Children and Young Adults with Acute Leukemia; An Exploratory, Observational Study by Dekker, Linde, Calkoen, Friso, Jiang, Yilin, Blok, Hilly, Spoon, Maike, Admiraal, Rick, Hoogerbrugge, Peter, Vormoor, Britta, Vormoor, Josef, Zwaan, C. Michel, Visscher, Henk, Bierings, Marc, Van Der Vlugt, Marieke, Van Tinteren, Harm, Laura Nijstad, A., Huitema, Alwin D.R., Van Der Elst, Kim, Pieters, Rob, Lindemans, Caroline A., Nierkens, Stefan

Get full text